A study of nearly 61,000 women in Denmark found that childhood obesity and overweight trajectories were associated with a lower likelihood of giving birth in adulthood. Women with higher BMI trajectories during childhood had a greater risk of childlessness, particularly at older ages.
The European Association for the Study of Obesity, dietitian societies, and other organizations have issued a consensus statement on the use of incretin drugs in obesity therapy. Key findings include the importance of medical nutrition therapy delivered by registered dietitians to complement incretin-based therapies. The statement also...
A nationwide study in Denmark shows a 7% reduction in triptan use for migraine treatment among women taking semaglutide for weight loss, with no significant change observed among men. The study suggests that weight loss and potential direct effects of GLP-1RA treatments may contribute to reduced migraine medication use.
A new study published at the European Congress on Obesity found that participants who underwent rapid weight loss lost significantly more weight than those who followed a gradual weight loss plan. After one year, the rapid weight loss group had achieved clinically meaningful weight loss and maintained it better than the gradual weight ...
A meta-analysis of 32 studies and 43,618 adults found a clinically relevant drop in blood pressure with obesity drugs for weight loss. The study shows that GLP-1RAs and MHRMs can induce significant BP reductions, with a 0.34 mmHg reduction per 1% weight loss.
A nationwide self-controlled cohort study found that GLP-1 class of obesity drugs were associated with a 26% fall in asthma exacerbations and a 14% drop in use of asthma inhaler reliever. The study suggests that weight loss, modulation of airway inflammation, and improvements in metabolic functions may improve asthma outcomes.
The European Association for the Study of Obesity, dietitian societies, and patients' organizations have issued a new consensus statement on using incretin drugs to treat obesity. The statement highlights the importance of medical nutritional therapy (MNT) and reinforces healthy dietary patterns. It also emphasizes the need to monitor ...
A systematic review found that obesity surgeries resulted in a higher proportion of fat-free mass loss compared to diet and exercise interventions. Incretin-based obesity drugs also led to greater fat-free mass loss than traditional weight loss methods.
A randomised controlled trial found semaglutide (Wegovy) significantly reduced BMI by 19% and fat mass in young adults with severe obesity, improving metabolic syndrome severity. The study suggests GLP-1 based treatment as a promising option for managing severe obesity in young people resistant to prior hospital-based care.
New research links excessive weight gain across adulthood to increased risks of various obesity-related cancers, including liver and colon cancer. The study found that steeper weight gain was associated with higher incidence rates.
A new study suggests that GLP-1 receptor agonists and GIP/GLP-1 receptor agonists can lead to substantial fat loss while preserving skeletal muscle mass in relative terms. The study found that muscle mass remained stable over time when accounting for changes in fat mass.
The article discusses how studying art history can aid in treating obesity, highlighting its long-standing depiction as a sign of prosperity and physical strength. Doctors can become more empathetic towards patients by understanding this historical context.
Research reveals bidirectional relationships between higher BMI and financial difficulties, loneliness and stress. Higher BMI may lead to stigma, social isolation and healthcare costs, while financial strain can limit access to healthy food and physical activity.
The updated algorithm incorporates evidence from multiple randomised clinical trials, highlighting the strength of tirzepatide for weight loss and semaglutide for liver disease management. The new guidance also recommends semaglutide for metabolic dysfunction-associated steatohepatitis remission.
New research finds lift capacity signs across Europe are outdated, failing to reflect current obesity trends. The study suggests that modernizing these signs is crucial for maintaining safety and comfort, while also acknowledging limitations in the investigation.
Patients on tirzepatide at maximum dose have seven times higher odds of maintaining weight loss compared to those who stop treatment. Those on the lower 5mg dose have four times higher odds, according to a new study published in The Lancet.
New research finds that participants in the ATTAIN-MAINTAIN trial maintained a significant percentage of weight loss when switched from injectable tirzepatide or semaglutide to daily oral orforglipron treatment. The study shows that nearly all weight loss achieved on injectable therapies can be maintained by switching to oral therapies.
The 'Ozempic Era' suggests a paradigm shift in understanding obesity, blaming commercial food systems rather than individual failings. Emerging medical data on GLP-1 agonists may drive policy responses to regulate ultra-processed foods.
A new study found that reducing annual working hours by 1% is linked to a small decline in obesity rates across 33 OECD countries, with the impact being stronger for men than women. Higher income levels and urbanization also showed significant correlations with lower obesity prevalence.
A pooled analysis of trials reveals semaglutide's safety and efficacy in individuals aged 65 years and older with obesity. The study found significant reductions in body weight and improvements in cardiometabolic risk factors, with a lower proportion of adverse events compared to placebo.
A new post-hoc analysis examined daily oral orforglipron treatment for obesity, with or without diabetes, in users aged 65 years and over. The study found that orforglipron significantly reduced body weight and improved blood sugar markers compared to placebo, with a similar safety profile to the overall ATTAIN clinical trial population.
A study of 65 countries found that consuming food away from home is consistently associated with obesity. Eating out is driven by sociodemographic factors such as sex, age, income, and education, and is linked to higher energy intake and body mass index.
A systematic review and meta-analysis of existing research found that increasing daily step count to around 8,500 can help prevent weight regain in people with overweight or obesity. Participants who increased their steps during the weight loss phase and maintained this level over time lost less weight and regained less weight.
A national survey in England found that over half of parents are frequently pressured by their children to buy unhealthy products, leading to almost three-quarters of these purchases. The study suggests the current food environment influences these requests, driven by instore and media marketing.
A new study found that patients who lost more weight with GLP-1 treatment had a lower risk of developing obesity-related conditions. In contrast, those who gained weight or only lost a small amount saw increased risks for osteoarthritis, chronic kidney disease, and heart failure.
Researchers found that women with prediabetes had persistent changes in gene expression in fat tissue after bariatric surgery, leading to impaired lipid metabolism and greater weight regain. Despite clinical improvement, these molecular alterations may reduce the ability of adipose tissue to adapt after weight loss.
A 42-year-old theory about children's body mass index (BMI) decrease before continuous rise is refuted by new analysis. Increasing muscle mass, not fat, causes the increase in BMI seen around age 5-7 years.
A new study reveals that men with obesity are more likely to develop abdominal fat and poorer liver health, while women with obesity are more susceptible to systemic inflammation and a less healthy blood fat profile. The findings highlight the importance of sex-specific research and targeted therapies for managing obesity.
A real-world study found that adults taking GLP-1 RAs for weight loss have significantly lower total energy and protein intake. The use of an AI-powered nutritional tracking app revealed that 88% of users were under national protein guidelines, with many skipping meals to reduce protein intake.
Researchers found a 21% increased risk of all stroke events for individuals with low birthweight compared to those above median weight. Low birthweight was also linked to increased risks of ischemic and intracerebral hemorrhage strokes, independent of gestational age and BMI.
A new study found that adults with obstructive sleep apnea have a 71% higher risk of cardiovascular events or death from any cause compared to those without the condition. People with OSA also experience higher rates of obesity, diabetes, osteoarthritis, anxiety, and depression.
Higher pancreatic fat content is associated with higher BMI, diastolic blood pressure, liver and visceral fat, and insulin resistance in young people with severe obesity. Measuring pancreatic fat content could help identify those at risk of developing cardiometabolic health issues.
A new study published in the journal Nutrients found that the traditional WHO body mass index (BMI) classification system misidentifies significant numbers of people as having overweight or obesity. Using dual-energy X-ray absorptiometry (DXA), researchers showed that more than one-third of those with obesity defined by BMI were actual...
A global panel of experts recommends a 10-year trial with 5,000 participants at high risk of cancer due to pre-cursor conditions. The trial will evaluate the potential efficacy of GLP-1 and dual receptor agonists in preventing obesity-related cancers.
The European Association for the Study of Obesity (EASO) has recommended Semaglutide and Tirzepatide as the first-line treatment for people living with obesity and most of its complications. These medications have been shown to be effective in promoting total weight loss and reducing complications such as obstructive sleep apnea, knee ...
A new analysis of 100 top TikTok videos about food noise found that half reference the use of medications, mainly anti-obesity drugs, to manage constant thoughts about food and eating. The study highlights the potential risks of misinformation on social media platforms like TikTok.
Research reveals rural preschoolers spend more time on screens and engage in less physical activity than their urban counterparts. The study found 24% of rural children have overweight or obesity, compared to 16% in urban areas.
A global survey found a significant disconnect between physicians' and patients' perceptions of obesity causes and treatment goals. Physicians tend to attribute obesity to behavioral causes, while patients cite biological factors as the primary cause.
SYNT-101 successfully redirects nutrient absorption to the lower intestine, promoting satiety and metabolic balance. The study demonstrated strong safety and tolerability profiles, as well as control of hunger and weight loss.
Researchers found that tirzepatide increases energy expenditure directly after treatment, while semaglutide reduces it. Both drugs aid weight loss by decreasing food intake and enhancing fat oxidation.
A new study published at the European Congress on Obesity suggests that GLP-1 agonist drugs can lead to a clinically relevant change in BMI for children with severe obesity. In this study, 30% of children who received GLP-1 drugs experienced a significant reduction in BMI, compared to around 27% of those who did not receive them.
Patients in an online obesity clinic achieved average weight loss of 16.7% after 64 weeks, similar to clinical trials of semaglutide, but using less than half the medication. The study found that personalized doses of semaglutide combined with behavioral therapy and support led to successful weight loss.
A new head-to-head study has shown that tirzepatide results in around 50% more weight loss than semaglutide in adults with obesity. The study found that tirzepatide led to an average weight loss of 20.2%, significantly higher than the 13.7% achieved with semaglutide.
A new analysis of the SELECT trial shows semaglutide reduces major cardiovascular events by 40% within 3-6 months, even before significant weight loss and full target dose. The study found that semaglutide's effects on reducing inflammation, blood sugar, and blood pressure may contribute to its early clinical benefits.
Researchers found that individuals who consumed collagen-enriched protein bars lost twice as much weight as a control group. The supplement also improved blood pressure, waist circumference, and liver health. Participants reported feeling less hungry and more full.
Research found that GLP-1 receptor agonists significantly reduced the risk of heart attacks, strokes, and other cardiovascular events. Treatment with these medications after bariatric surgery was associated with a 67% lower risk of major adverse cardiovascular events or death.
A child's body mass index (BMI) at six years old is a strong predictor of their risk of overweight or obesity at 18. Reaching a healthier weight before six can reduce this risk, but returning to it later does not have the same effect.
A Danish study found that adverse waist-to-height ratio trajectories in childhood are associated with increased cardiometabolic risk at age 10. Children with gradually increasing central obesity showed early signs of metabolic and cardiovascular risk, including elevated blood pressure and insulin resistance.
A Swedish study found that individuals who lived with obesity as children are four times more likely to be on sick leave aged 25 than their peers in the general population. The study also revealed that those with severe childhood obesity were three times more likely to be on long-term sick leave.
Researchers found that GLP-1 receptor agonists have a direct effect on reducing obesity-related cancer beyond weight-loss, with a 41% lower relative risk compared to bariatric surgery. The study also suggests that these medications work through multiple mechanisms, including reducing inflammation.